Lexington, MA, United States of America

Jutta Deckert

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 3.9

ph-index = 6

Forward Citations = 121(Granted Patents)


Location History:

  • Waltham, MA (US) (2016)
  • Lexington, MA (US) (2012 - 2022)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Jutta Deckert: Innovator in Cancer Treatment

Introduction

Jutta Deckert is a prominent inventor based in Lexington, MA (US), known for her significant contributions to cancer treatment through innovative immunoconjugates. With a total of 13 patents to her name, she has made remarkable strides in the field of oncology.

Latest Patents

Among her latest patents are the "Anti-CD37 immunoconjugate and anti-CD20 antibody combinations" and "CD37-binding molecules and immunoconjugates thereof." The first patent provides methods for administering immunoconjugates that bind to CD37, such as IMGN529, in combination with antibodies that bind to CD20, specifically targeting cancer patients. The second patent introduces novel anti-cancer agents, including antibodies and immunoconjugates that bind to CD37, along with methods for using these agents to inhibit tumor growth.

Career Highlights

Jutta has worked with notable companies in the pharmaceutical industry, including Debiopharm International, S.A. and Immunogen, Inc. Her work has focused on developing innovative therapies that enhance the effectiveness of cancer treatments.

Collaborations

Throughout her career, Jutta has collaborated with esteemed colleagues such as Peter U Park and Daniel J Tavares, contributing to the advancement of cancer research and treatment methodologies.

Conclusion

Jutta Deckert's innovative work in the field of cancer treatment has established her as a leading inventor in immunoconjugate technology. Her patents reflect her commitment to improving patient outcomes and advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…